Bio-Rad Launches Nuvia wPrime 2A Media for Scalable Biomolecule Purification

15 January 2025 | Wednesday | News

The new mixed-mode chromatography resin offers advanced purification for monoclonal antibodies, adeno-associated viruses, and more, enabling efficient, large-scale bioproduction and manufacturing processes.
Picture Courtesy | Public Domain

Picture Courtesy | Public Domain

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced the launch of Nuvia wPrime 2A Media, a scalable weak anion exchange and hydrophobic interaction (AEX-HIC) mixed-mode chromatography resin for small- to large-scale biomolecule purification. Bio-Rad's partners that aided in the resin’s development successfully used the resin to remove host cell proteins, high and low molecular weight aggregates and impurities, and DNA from monoclonal and bispecific antibodies, and adeno-associated virus.

Built upon Bio-Rad's Nuvia bead technology, Nuvia wPrime 2A Media features a polyacrylamide (acrylamide polymer) base bead that can be used for laboratory- and small-scale purification workflows, as well as for pilot-scale bioproduction and manufacturing-scale downstream processing. Bio-Rad’s Nuvia resins are designed to have minimal non-specific binding reactions, due to the hydrophilic nature of the bead polymer, and maintain a constant dynamic binding capacity over a wide range of flow rates. The Nuvia bead allows for fast mass transfer, is chemically and mechanically stable over a wide range of conditions and is easy to pack.

Developed in collaboration with Bio-Rad’s partners in industrial biotherapeutic production, Nuvia wPrime 2A Media provides a wide purification design space. The charge state of the resin’s functional ligand can be modulated by the pH of the buffer, enabling the purification of otherwise difficult-to-separate biomolecules from other impurities.

"Bio-Rad is committed to developing innovative chromatography resins for a wide variety of customer needs, and to advancing the efforts of researchers and therapy manufacturers alike in saving lives," said Diab Elmashni, Director, Process Chromatography Business at Bio-Rad Laboratories. "As a leader in multimodal chromatography technology, Bio-Rad’s Nuvia and CHT™ Ceramic Hydroxyapatite families of resins and media are integral to pharmaceutical development and industrial-scale purification for many customers worldwide This new resin is unique to the market and addresses customer requests for a scalable, weak anion exchange and hydrophobic interaction mixed-mode resin."

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close